AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing

Contributed by: Business Wire

Logo

Tags

Oncology

Health

Stem Cells

Surgery

Other Health

Pharmaceutical

Biotechnology

AdvanCell

More Like This

AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer

AdvanCell to participate in Jefferies Global Healthcare Conference in London

AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer

AdvanCell to Present Promising Clinical Trial Results of ADVC001, a Novel Lead-212-based PSMA-targeted Alpha Therapy for Prostate Cancer, at ESMO 2025

AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth

AdvanCell Proudly Announces $18M in Federal Funding from the Medical Research Future Fund (MRFF) Frontiers Initiative for ‘Defeating Prostate Cancer with Targeted Alpha Therapy’

PR Newswire associated0

Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First-in-class ADC Pipeline

PR Newswire associated0

ARTBIO Announces $132 Million Series B Financing to Advance Pipeline of Alpha Radioligand Therapies and Expand Manufacturing and Supply Chain Infrastructure